Soleno Therapeutics (SLNO) Cash & Equivalents (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash & Equivalents data on file, last reported at $133.0 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $133.0 million, up 63.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $133.0 million (up 63.56% YoY), and the FY2025 annual result was $70.1 million, down 20.27% from the prior year.
• Cash & Equivalents grew to $133.0 million in Q1 2026 per SLNO's latest filing, from $70.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $246.7 million in Q3 2025 and troughed at $7.9 million in Q1 2023.
• A 5-year average of $69.4 million and a median of $52.4 million in 2023 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 1062.04% in 2023 and fell as far as 72.76% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $14.6 million in 2022, then surged by 1062.04% to $169.7 million in 2023, then tumbled by 48.18% to $87.9 million in 2024, then declined by 20.27% to $70.1 million in 2025, then soared by 89.75% to $133.0 million in 2026.
• Business Quant data shows SLNO's Cash & Equivalents at $133.0 million in Q1 2026, $70.1 million in Q4 2025, and $246.7 million in Q3 2025.